跳到正文
原文
Merck· @Merck · X·· 22 天前精选AI 评分75
AI 导读

默沙东公布其研究性TROP2抗体偶联药物(ADC)在部分子宫内膜癌患者中开展的III期试验结果,并在ESMO主席论坛上首次报告。该药物尚未获批,具体疗效与安全性数据未在原文中披露。

推荐理由

默沙东公布其TROP2 ADC在子宫内膜癌III期试验的结果,并在ESMO主席论坛首次报告,可供判断该靶点在妇科肿瘤中的开发进展。

正文

Today, we announced findings from our Phase 3 trial evaluating our investigational TROP2-directed antibody-drug conjugate (ADC) in certain patients with endometrial cancer. The results were presented for the first time during a Presidential Symposium at ESMO. https://go.merck.com/~5wh

来源:Merck · x.com